DTAB Approves Notification System for Application of new drug, IND for clinical trial, BA-BE study
New Delhi: With an aim to streamline the process for permission to manufacture new drugs and investigational new drugs (IND) for clinical trials, bioavailability/bioequivalence studies (BA/BE), or for examination tests and analysis, the Drugs Technical Advisory Board (DTAB) has agreed to introduce the notification system for applications to manufacture drugs for analytical and preclinical testing, excluding sex hormones, cytotoxic drugs, beta-lactams, biologics with live microorganisms, and narcotics and psychotropic drugs.
In addition, the board has agreed to reduce timelines for processing applications for permission for other categories of new drugs and IND under Chapter VIII of the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules), from 90 working days to 45 working days.
This came in line with the proposal to amend NDCT Rules, 2019, for streamlining the process for permission to manufacture new drugs and investigational new drugs for clinical trials, BA/BE studies, or for examination tests and analysis:
The matter was discussed during the 92nd DTAB meeting held on April 24, 2025.
The Board was apprised with respect to streamlining the process for issuance of permission to manufacture new drugs or investigational new drugs for clinical trials, BA/BE studies, or examination tests and analysis.
DTAB deliberated the matter and agreed to the following proposed amendment under the NDCT Rules, 2019:
1. Notification system may be introduced for applications to manufacture for Analytical and Preclinical Testing of drugs excluding sex hormones, cytotoxic, beta lactam, Biologics with live microorganism and narcotics & psychotropic drugs.2. To reduce timelines for processing of applications for permission for other categories of new drug and IND under Chapter VIII of NDCT Rules from 90 working days to 45 working days
Also Read: CDSCO issues Revised Export NOC Guidance document for Manufacture of Unapproved, Approved New Drugs
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.